11th May 2022 14:34
11 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company has been notified that on 10 May 2022 Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust purchased ordinary shares ("Shares"), on behalf of Susanne Munksted, a PDMR, in respect of her purchase of Shares pursuant to the Company's Global Share Incentive Plan ("the SIP Scheme") for employees. These purchases will be made each month until further notice.
In accordance with the SIP Scheme, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 2:1.
Enquiries:
Diaceutics PLC | |
Nick Roberts, Chief Financial Officer | Via Alma PR |
Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
Ben Maddison | |
Stewart Wallace | |
Nick Adams | |
Alma PR | Tel: +44(0)20 3405 0205 |
Caroline Forde | |
Kieran Breheny | |
Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Susanne Munksted | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Chief Precision Medicine Officer and PDMR | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics PLC | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary shares of £0.002 each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP") | |||||
c. | Price(s) and volume(s) | Share purchase: | |||||
Price(s) | Volume(s) | ||||||
1.13 p | 130 | ||||||
Conditional share award: | |||||||
Price(s) | Volume(s) | ||||||
Nil | 260 | ||||||
e. | Date of the transaction | Share purchase and Conditional share award: 10 May 2022 | |||||
f. | Place of the transaction | Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market | |||||
Related Shares:
Diaceutics